Advertisement

Antibodies to von Willebrand factor in von Willebrand disease

  • P. M. Mannucci
  • A. B. Federici
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)

Abstract

The occurrence of an alloantibody directed against von Willebrand factor in a multitransfused patient with severe (type III) von Willebrand disease was first reported in 2 consecutive studies by Sarji et al. (1974) and Stratton et al. (1975). After this, 14 additional cases of alloantibodies were described and reviewed by Mannucci and Mari (1984). A survey carried out on behalf of the World Federation of Hemophilia identified 6 additional cases that, added to the 15 cases previously reported, bring to 21 the total number of patients reported so far with anti-von Willebrand factor alloantibodies (Mannucci and Cattaneo, 1991). In the frame of the survey, Hanna (1989) reported an antibody directed towards factor VIII (F.VIII) in a girl with severe von Willebrand disease. Since this antibody did not apparently react with von Willebrand factor, it will not be reviewed here.

Keywords

Factor VIII Bleeding Time Factor Viii Concentrate Multitransfused Patient Factor VIII Procoagulant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bloom AL, Peake IR, Furlong RA and Davies BL. High potency factor VIII concentrate: more effective than cryoprecipitate in a patient with von Willebrand’s disease and inhibitor. Thromb Res 16: 847 (1979).PubMedCrossRefGoogle Scholar
  2. Egberg N and Blomback M. On the characterization of acquired inhibitors to ristocetin-induced platelet aggregation found in patients with von Willebrand’s disease. Thromb Res 9: 527 (1976).PubMedCrossRefGoogle Scholar
  3. Ginsburg D and Sadler JE. von Willebrand disease: a database of point mutations, insertions and deletions. Thromb Haemostas 69: 177 (1993).Google Scholar
  4. Hanna WT. Replacement therapy for surgery in type III von Willebrand patient with inhibitors to factor VIII procoagulant. Thromb Haemostas 62: 224 (1989) (abstract).Google Scholar
  5. Lenk H, Weissbach G and Donula M. Ein Hemmkorper bei von Willebrand Jurgens- Syndrome and seine Wirkung aur die Eigenschaften des Factor VIII molekuls. Folia Haematol 105: 826 (1978).Google Scholar
  6. Lopez-Fernandez MF, Martin R, Lopez-Berges C, Ramos F, de Bosch N and Battle J. Further specific characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease. Blood 72: 116 (1988).PubMedGoogle Scholar
  7. Lopez-Fernandez MF, Martin R, Lopez-Berges C, Ramos F, de Bosch N and Battle J. Further specific characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease. Blood 72: 116 (1988).PubMedGoogle Scholar
  8. Mannucci PM, Meyer D, Ruggeri ZM, Koutts J, Ciavarella N and Lavergne JM. Precipitating antibodies in von Willebrand’s disease. Nature 262: 141 (1976).PubMedCrossRefGoogle Scholar
  9. Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD and Mowbray JF. Precipitating antibodies to factor VIII-von Willebrand factor in von Willebrand’s disease: effects on replacement therapy. Blood 57: 25 (1981).PubMedGoogle Scholar
  10. Mannucci PM and Mari D. Antibodies to factor VTII/von Willebrand factor in congenital and acquired von Willebrand’s disease. In: LW Hoyer ed. Factor Villi inhibitors. New York: Alan R. Liss, 109 (1984).Google Scholar
  11. Mannucci PM, Bloom A, Larrieu MJ, Nilsson IM and West RR. Atherosclerosis and von Willebrand factor. Prevalence of severe von Willebrand disease in Western Europe and Israel. Br J Haematol 57: 166 (1984).Google Scholar
  12. Mannucci PM, Tamaro G, Nerchi G, Candotti G, Federici A, Altieri D and Tedesco F. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Hematol 39: 467 (1987).CrossRefGoogle Scholar
  13. Mannucci PM and Cattaneo M. Alloantibodies in congenital von Willebrand disease. Res Clin Lab 21: 119 (1991).CrossRefGoogle Scholar
  14. Maragall S, Castillo R, Ordinas A, Iiendo F and Rodriquez M. Inhibition of Willebrand factor in von Willebrand’s disease. Thromb Res 14: 495 (1979).PubMedCrossRefGoogle Scholar
  15. Miller CH, Bussel JB and Hilgartner MW. Characteristics of inhibitors in severe von Willebrand’s disease. Thromb Haemost 50: 34 (1983) (abstract).Google Scholar
  16. Ngo K, Glotz VT, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand’s disease. Proc Natl Acad Sci USA 85: 2753 (1988).PubMedCrossRefGoogle Scholar
  17. Peake IR, Lidde CB, Moodie P, et al. Severe type III von Willebrand’s disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood 72: 6544 (1990).Google Scholar
  18. Ruggeri ZM, Ciavarella N, Mannucci PM, Molinari A, Dammaco F, Lavergne JM and Meyer D. Familial incidence of precipitating antibodies in von Willebrand’s disease: a study of four cases. J Lab. Clin Med 94: 60 (1979).PubMedGoogle Scholar
  19. Sarji KE, Stratton RD, Wagner RH and Brinkhous KM. Nature of von Willebrand factor. A new assay and a specific inhibitor. Proc Natl Acad Sci USA 71: 2937 (1974).Google Scholar
  20. Shelton-Inloes BB, Chebab FF, Mannucci PM, Federici AB and Sadler JE. Gene deletions correlate with the development of antibodies in von Willebrand disease. J Clin Invest 79: 1459 (1987).PubMedCrossRefGoogle Scholar
  21. Shoa’i I, Lavergne JM, Ardaillou N, Obert B, Ala F and Meyer D. Heterogeneity of von Willebrand’s disease; study of 40 Iranian cases. Br J Haematol 37: 67 (1977).PubMedGoogle Scholar
  22. Stratton RD, Wagner RH, Webster WP and Brinkhous KM. Antibody nature of circulating inhibitor of plasma von Willebrand factor. Proc Natl Acad Sci USA 72: 4167 (1975).PubMedCrossRefGoogle Scholar
  23. Zhang ZP, Lindstedt M, Falk G, Blomback M, Egberg N and Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and I. Am J Hum Genet 51: 850 (1992).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • P. M. Mannucci
    • 1
  • A. B. Federici
    • 1
  1. 1.Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Institute of Internal Medicine and IRCCS Maggiore HospitalUniversity of MilanoItaly

Personalised recommendations